Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on May 8, 2015, covering events occurring on May 4, 2015, and May 7, 2015. The filing details the entry into material definitive agreements regarding the company's HydraGuard water treatment devices and the appointment of a new director.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. However, it discloses specific contractual financial obligations and revenue-sharing terms:
- Minimum Purchase Commitment: Nephros agreed to purchase a minimum of €1,000,000 (approximately $1,130,000) from Medica S.p.A. for calendar year 2015.
- Royalty Obligations: Nephros will pay Medica a 3% royalty on net sales until December 31, 2022. If Nephros sublicenses rights to a third party, the fee changes to €2.00 (approximately $2.25) per HydraGuard unit.
- Sublicense Revenue: Under the agreement with CamelBak Products, LLC, Nephros will receive a percentage of gross profit on U.S. military sales and a fixed per-unit fee on other sales.
Material Changes and Agreements
The filing reports two primary material changes:
- Amendment with Medica S.p.A.: On May 4, 2015, Nephros entered into a Second Amendment to its License and Supply Agreement. This established the 2015 minimum purchase amount and clarified royalty structures, including the per-unit fee alternative for sublicensed products. Italy remains excluded from the worldwide license.
- Sublicense with CamelBak: On May 6, 2015, Nephros granted CamelBak an exclusive, worldwide (excluding Italy) sublicense to market and sell HydraGuard devices. The agreement includes performance thresholds; if CamelBak fails to meet minimum annual fees, the exclusive status may convert to non-exclusive for non-military sales. The agreement expires on December 31, 2022.
Management Commentary, Risks, and Corporate Governance
Board Appointment: On May 7, 2015, the Board appointed Malcom Persen as a director and Chair of the Audit Committee. Mr. Persen brings experience in renewable energy contracting and finance, having previously served as CFO for Radyne Corporation and held executive roles at Ironco Enterprises and Avnet, Inc.
Risks and Contingencies: The Sublicense Agreement with CamelBak contains termination and conversion clauses. Nephros may terminate the sublicense in specific geographic areas if CamelBak develops competing products. If sales of a competing product exceed HydraGuard sales in a specific area, the exclusive sublicense may be converted to non-exclusive for that area.
Investor Verification Checklist
- Verify the full text of the Second Amendment and Sublicense Agreement, which are filed as exhibits to the Form 10-Q for the quarter ending June 30, 2015.
- Monitor CamelBak's ability to meet the minimum annual fees to maintain exclusive sublicense status.
- Track the 3% royalty payments or per-unit fees payable to Medica S.p.A. as sales volumes fluctuate.
- Assess the impact of the new Audit Committee Chair, Malcom Persen, on financial oversight and governance.